OxySure Therapeutics, Inc. - FORM 10-K - EX-32 - CERTIFICATION - April 15, 2014

Attached files

file filename
10-K - ANNUAL REPORT - OxySure Therapeutics, Inc.f10k2013_oxysure.htm
EX-10.42(2) - PP AVIATION CORPORATION, TEAMING AGREEMEN - OxySure Therapeutics, Inc.f10k2013ex10xlii2_oxysure.htm
EX-10.1.10 - FIFTH AMENDMENT TO SECOND EMPLOYMENT AGREEMENT - OxySure Therapeutics, Inc.f10k2013ex10i10_oxysure.htm
EX-10.3.5 - SINACOLA COMMERCIAL PROPERTIES, LTD. LEASE AMENDMENT, DATED DECEMBER 31, 2013 - OxySure Therapeutics, Inc.f10k2013ex10iii5_oxysure.htm
EX-10.40 - ALPHA CAPITAL ANSTALT ET AL, SECURITIES PURCHASE AGREEMENT - OxySure Therapeutics, Inc.f10k2013ex10xl_oxysure.htm
EX-10.42 - PP AVIATION CORPORATION, TEAMING AGREEMENT - OxySure Therapeutics, Inc.f10k2013ex10xlii_oxysure.htm
EX-14.1.1 - AS AMENDED CODE OF ETHICS - OxySure Therapeutics, Inc.f10k2013ex14i1_oxysure.htm
EX-31.2 - CERTIFICATION - OxySure Therapeutics, Inc.f10k2013ex31ii_oxysure.htm
EX-23.2 - CONSENT - OxySure Therapeutics, Inc.f10k2013ex23ii_oxysure.htm
EX-10.42(1) - PP AVIATION CORPORATION, TEAMING AGREEMENT - OxySure Therapeutics, Inc.f10k2013ex10xlii1_oxysure.htm
EX-10.1.11 - AS AMENDED SECOND EMPLOYMENT AGREEMENT - OxySure Therapeutics, Inc.f10k2013ex10i11_oxysure.htm
EX-31.1 - CERTIFICATION - OxySure Therapeutics, Inc.f10k2013ex31i_oxysure.htm
EX-10.3.6 - SINACOLA COMMERCIAL PROPERTIES, LTD. LETTER AGREEMENT, DATED DECEMBER 31, 2013 - OxySure Therapeutics, Inc.f10k2013ex10iii6_oxysure.htm
EX-10.11.6 - EXTENSION OF THIRD MORATORIUM ON PAYMENT AGREEMENT, - OxySure Therapeutics, Inc.f10k2013ex10xi6_oxysure.htm
EX-10.11.5 - THIRD MORATORIUM ON PAYMENT AGREEMENT, VENCORE SOLUTIONS, LLC DATED AUGUST 2, 2013 - OxySure Therapeutics, Inc.f10k2013ex10xi5_oxysure.htm
EX-10.38 - WALL STREET BUY SELL HOLD CONSULTING AGREEMENT - OxySure Therapeutics, Inc.f10k2013ex10xxxviii_oxysure.htm
EX-10.41 - ALPHA CAPITAL ANSTALT ET AL, FORM OF WARRANT ISSUED PURSUANT TO SECURITIES PURCHASE AGREEMENT - OxySure Therapeutics, Inc.f10k2013ex10xli_oxysure.htm
EX-10.39 - CERTIFICATE OF DESIGNATION OF SERIES B CONVERTIBLE PREFERRED STOCK - OxySure Therapeutics, Inc.f10k2013ex10xxxix_oxysure.htm
Exhibit 32
 
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report of OxySure Systems, Inc. (the “Company”) on Form 10-K for the period ending December 31, 2013 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Julian T. Ross, Chief Executive Officer and Chief Financial Officer of the Company, respectively, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge and belief:

 
1.
The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 
2.
The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

Date: April 15, 2014
 
/s/ Julian T. Ross
  
Julian T. Ross
  
Chief Executive Officer and Chief Financial Officer

OxySure Therapeutics, Inc. Reports